Clear Labs, a San Carlos, CA-based provider of next-generation sequencing (NGS) platforms for diagnostics, raised $30M in Series D funding.
The round was led by a strategic investor, along with participation from existing investors, including Counterpoint Global (Morgan Stanley), Felicis, GV, HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, Wing Venture Capital, and funds and accounts advised by T. Rowe Price Associates, Inc.
The company intends to use the funds to continue accelerating the development and adoption of its NGS solutions while scaling operations to meet the demand for fully automated turnkey genomics solutions worldwide.
Led by CEO Dr. Sasan Amini, Clear Labs develops next-generation sequencing (NGS) to simplify complex diagnostics for the clinical and applied markets. With its platform that integrates DNA sequencing, robotics, and cloud-based bioinformatics and analytics, the company empowers healthcare institutions with everything they need to perform advanced genomics in-house in their own labs.
Clear Labs is also adding Kevin Keegan, Becton Dickinson’s Vice President and Global Platform Leader, Molecular Diagnostics, to its Board of Directors. Keegan was previously Illumina’s Vice President and General Manager of Oncology.
FinSMEs
13/01/2025